Skip to content

Abdominal muscle balloon in the treatment of lower extremity arteriosclerotic obliterans (ASO) Efficacy and safety: a prospective, single-blind, randomized control study

Abdominal muscle balloon in the treatment of lower extremity arteriosclerotic obliterans (ASO) Efficacy and safety: a prospective, single-blind, randomized control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091991
Enrollment
Unknown
Registered
2024-11-07
Start date
2024-11-15
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower extremity arteriosclerosis obliterans, ASO

Interventions

Experimental group:Binding peripheral balloon
Control group:Common balloon

Sponsors

Tangdu Hospital,Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age > 40 years old, gender is not limited; ? The clinical manifestations were intermittent claudication or severe limb ischemia (Rutherford grade 2)Up); ?The main lesion site was superficial femoral artery or popliteal artery, with stenosis =70% and accompanied by symptoms; ? At least one vessel in the distal outflow tract has unobstructed blood flow; ? Target blood vessel diameter 2.5-6.0mm; ? Target lesion length < 180mm; ? Sign informed consent and be able to understand and comply with the requirements of the test protocol.

Exclusion criteria

Exclusion criteria: ?Serum creatinine clearance is less than 30ml/min; ?Blood routine was significantly abnormal, white blood cell count 14.0*10^9/L, platelet count 500*10^9/L; ? Patients with acute thrombosis requiring thrombolysis or thrombolysis; ? subknee femoral artery restenosis in stent; ? Target lesions that cannot be passed through the guide wire; ? Those who are expected to require amputation before intervention; ?Patients with a history of stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within the first three months of enrollment; ?Participants in other clinical trials that may interfere with this trial; ? Pregnant and lactating women; ? Patients with known allergies to the medical devices and drugs involved in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of intraoperative flow-restricted dissection;< 30% diameter narrow;Ultrasound examination by surgeon;Postoperative vascular patency rate;TLR Incidence rate;AE Incidence rate;SAE Incidence rate;

Secondary

MeasureTime frame
Technical success rate;Remedial stent placement rate;ABI;

Countries

China

Contacts

Public ContactZhang Zhang

Tangdu Hospital,Fourth Military Medical University

zhangz0613@163.com+86 136 7922 9782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026